Genmab — Juni 2022
-
ca. 450 point over 14 dage er vel også godkendt med mindre nohope skal vurdere
-
Stroka..Så vidt jeg husker har Genmab i 2019, 2020 og 2021 steget flot hen over sommeren. Vi krydser fingre for en gentagelse i 2022.
-
Med reference til aktietilbagekøb i 2021, steg kursen til ca. 2600 fra 1900 over 4 måneder, hvor der blev tilbagekøbt 200.000 aktier.... Nu skal der købes 370.000 og den gennemsnitlige handelsvolumen er umiddelbare lavere disse dage sammenlignet med 2021
-
USA/middag: Aktier ramt af recessionsfrygt - værste halvår siden 1970 https://www.proinvestor.com/investornyt/844764/usa-middag-aktier-ramt-af-recessionsfrygt-vaerste-halvar-siden-1970
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody
-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) -
Jeg holder en lille fest for mig selv
-
Thx´
-
-
Man vurderer, at markedet skal informeres om væsentlige forhold
-
Da man ansøgte Tisotumab Vedotin kom selskabsmeddelelsen først da FDA havde accepteret ansøgningen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind